Where care and collaboration meet, to make a difference when it matters most

Mundipharma Pharmaceuticals Limited
Unit 10
United Drug House
Magna Drive
Magna Business Park
Citywest Road
Dublin 24
D24 XKE5
Ireland

Tel: +353 1 2063800
Email: [email protected]

Media enquiries

Global media office Email: [email protected]

Careers

If you’re looking for a role where you can make a difference when it matters most, we want to hear from you. Click here to see the current opportunities to join our team.

Report a side effect

Patient safety is very important to us.

If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in the package leaflet. By reporting side effects, you can help provide more information on the safety of medicine.

Adverse events should be reported to:
HPRA Pharmacovigilance
Earlsfort Terrace
IRL – Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
Website: www.hpra.ie
Email: [email protected]

Adverse events should also be reported to Mundipharma Pharmaceuticals Limited on [email protected] or by phone on +44 174 882 8867.

Please provide as much information as you can:

  • About the person who experienced the adverse event: initials, gender, age or date or birth
  • About the person contacting us for this report: your name, contact details and professional qualification if you are a healthcare professional, and confirmation that we can contact you to request additional information
  • About the adverse event: the symptom(s) experienced, when it started, when it stopped or if it is still ongoing
  • About the Mundipharma medicinal product involved: product name, dose being taken, Lot or Batch Number, and date treatment was started and/or stopped

Mundipharma and companies within the Mundipharma global network of independent associated companies are required by law to collect certain minimum information relating to persons who have suffered an adverse event to the company’s medicinal product in order to monitor the safety of its medicinal products. This includes reviewing safety data from clinical studies and collecting reports of adverse events. Drug safety staff may contact you if additional information is required to fully document the adverse event report.

All the information and personal data you share with us will be protected and kept confidential in line with our Data Privacy Policy and local regulations and guidance. Your information will be used for the purpose of drug safety surveillance and to enable us to deal with your enquiry appropriately.

It may be shared with health authorities and other third parties who are also responsible for drug safety surveillance. If you are a patient, you can ask someone else (e.g., your doctor or pharmacist) to send the report if you do not wish to give us your name. Find more information about how we protect your personal data.

Disclosure of payments

To advance patient care, like many other pharmaceutical organisations, we work collaboratively with healthcare professionals and healthcare organisations.

Our policies and procedures provide instructions to employees on the rules and approval processes required for engagements with healthcare professionals, to help ensure that such engagements are only for lawful and legitimate business needs, are appropriately documented, are compensated according to fair market value, and do not interfere with a healthcare professional’s independent medical judgment.

In accordance with this and to ensure transparency of our partnerships, we will publish the full disclosure of all Transfers of Value (TOV) to healthcare professionals and healthcare organisations in accordance with the requirements of Annex V of the IPHA Code of Practice for the Pharmaceutical Industry (The Code). In accordance with the requirements of Annex III of The Code, we will also publish a list of patient organisations to which we provide financial support and/or significant indirect/non-financial support.

Methodology for disclosing Transfers of Value (TOV)
The details of the TOV are gathered from our internal finance and reporting systems. Data is then used to populate the template. This template was developed to ensure clarity of data and ease of understanding. All payments are reported in Euro. Where payments were made in other currencies Mundipharma Pharmaceuticals Limited has used its own internal currency exchange rate to convert the amount to Euro. Details of these exchange rates are available on request. All amounts disclosed are exclusive of VAT. Disclosures for the previous year will be made within 6 months of the following calendar year e.g., all TOVs for the calendar year 2015 will be made public by end June 2016 at the latest. Each annual statement will contain all TOVs which actually occurred during that calendar year.

Where possible, all TOVs will be disclosed on an individual basis. For TOVs, where certain information cannot be disclosed on an individual basis for valid legal reasons, the amount attributable will be disclosed on an aggregate basis. The number of recipients involved will be stated together with the percentage of all recipients that they represent and the aggregate amount attributable to TOVs to such recipients.

This information will remain on a central report hosted by IPHA www.transferofvalue.ie for three years from the time of disclosure.

Mundipharma Integrity Line

We take compliance very seriously and adhere to the laws and regulations of the countries in which we operate. If you think something is not right, please speak up so that we can address your concerns and take appropriate action.

We also encourage you to raise questions or suggestions for improvement regarding our policies and procedures.

Mundipharma prohibits any form of retaliation towards an individual that raises a concern in good faith.

Please use the Mundipharma Integrity Line to raise your questions or concerns.